New drugs in the management of the irritable bowel syndrome

Drugs
M J Farthing

Abstract

Irritable bowel syndrome (IBS) continues to provide a major therapeutic challenge to clinicians and those involved in drug development. It seems unlikely from the data before us that this multisymptom syndrome with peripheral and central components is likely to respond reliably in all patients to the same single agent. There is still a lack of well designed, appropriately powered, randomised clinical trials and the problems of dealing with the high placebo response rate in this group of patients remains a dilemma for trial designers. There are, however, some new ideas, particularly those relating to the role of hyperalgesia in IBS. For many patients, abdominal pain and bloating are the most distressing symptoms of this disease and the new drugs targeted at pain control, such as kappa agonists and serotonin antagonists (5-HT3) and possibly 5-HT4), may eventually find a place in the clinical management of this syndrome. Other candidates include somatostatin analogues and antidepressants, the latter predominantly for their effects on increasing pain threshold. More speculative new drugs for IBS include cholecystokinin antagonists such as loxiglumide and the gonadotrophin-releasing hormone analogue, leuprorelin (leuprolide). The re...Continue Reading

Citations

Jul 25, 2000·Clinical Chemistry and Laboratory Medicine : CCLM·E M KittlK R Huber
Sep 20, 2005·Current Gastroenterology Reports·Michael J G Farthing
Nov 30, 2000·Current Treatment Options in Gastroenterology·A D Sperber, D A Drossman
Dec 6, 2000·European Journal of Pharmacology·H ItoT Yamaguchi
Mar 13, 2002·Pharmacology, Biochemistry, and Behavior·Brian J Jones, Thomas P Blackburn
Jun 21, 2007·International Journal of Technology Assessment in Health Care·Margriet Moret-HartmanJohn Grin
Oct 7, 2006·Current Opinion in Gastroenterology·M D Gershon
Jan 11, 2003·American Journal of Therapeutics·Amir GarakaniPrakash S Masand
Apr 17, 2003·Postgraduate Medical Journal·M C GunnJ C Mansfield
Oct 18, 2002·Journal of Clinical Pharmacy and Therapeutics·B W JonesF Song
Feb 22, 2002·Gastroenterology Nursing : the Official Journal of the Society of Gastroenterology Nurses and Associates·M Heitkemper, M Jarrett
Apr 6, 2004·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Viola Andresen, Stephan Hollerbach
Jun 5, 2007·Best Practice & Research. Clinical Gastroenterology·Michael J G Farthing
Oct 21, 2015·Autonomic Neuroscience : Basic & Clinical·Elin SandEva Ekblad
Sep 5, 2006·Alimentary Pharmacology & Therapeutics·E A MayerS Bradesi
Aug 25, 2004·Best Practice & Research. Clinical Gastroenterology·Michael J G Farthing
Jan 5, 2002·Expert Opinion on Pharmacotherapy·Joseph Ahn, Eli D Ehrenpreis
Feb 18, 2006·Scandinavian Journal of Gastroenterology·Patrick P J Van Der VeekAd A M Masclee
Dec 13, 2005·Neurogastroenterology and Motility : the Official Journal of the European Gastrointestinal Motility Society·L DegenC Beglinger
Dec 1, 1998·Nutrition Research Reviews·A D ShawG J Davies
Sep 22, 2000·Current Review of Pain·S M TurnerJ S Hill
Oct 19, 2007·The Cochrane Database of Systematic Reviews·B W EvansP J Whorwell
Mar 8, 2002·Disease-a-month : DM·Richard B Birrer

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.